Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maral Saadati

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
The Journal of Clinical Investigation|March 3, 2015
Corrigendum. Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosisChristoph Reissfelder, Slava Stamova, Christina Gossmann, et al.
Frontiers in Immunology|May 19, 2023
Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantationMarie Luise Hütter-Krönke, Adela Neagoie, Igor Wolfgang Blau, et al.
Haematologica|July 20, 2023
Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemiaRabia Shahswar, Gernot Beutel, Razif Gabdoulline, et al.
Cancer Research|September 17, 2016
Integrative Genome-Scale Analysis Identifies Epigenetic Mechanisms of Transcriptional Deregulation in Unfavorable NeuroblastomasKai-Oliver Henrich, Sebastian Bender, Maral Saadati, et al.
Leukemia|October 3, 2023
Correction: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patientsEkaterina Jahn, Maral Saadati, Pierre Fenaux, et al.
Leukemia|August 17, 2023
Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patientsEkaterina Jahn, Maral Saadati, Pierre Fenaux, et al.
Hemasphere|January 16, 2025
Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with <i>NPM1</i>-mutated AMLSibylle Cocciardi, Maral Saadati, Nina Weiß, et al.
Leukemia|August 3, 2022
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trialNikolaus Jahn, Ekaterina Jahn, Maral Saadati, et al.
Blood Advances|April 29, 2022
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplicationsHartmut Döhner, Daniela Weber, Julia Krzykalla, et al.
Blood|January 6, 2026
Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemiaHartmut Döhner, Daniela Späth, Maral Saadati, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
The Journal of Clinical Investigation|March 3, 2015
Corrigendum. Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosisChristoph Reissfelder, Slava Stamova, Christina Gossmann, et al.
Frontiers in Immunology|May 19, 2023
Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantationMarie Luise Hütter-Krönke, Adela Neagoie, Igor Wolfgang Blau, et al.
Haematologica|July 20, 2023
Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemiaRabia Shahswar, Gernot Beutel, Razif Gabdoulline, et al.
Cancer Research|September 17, 2016
Integrative Genome-Scale Analysis Identifies Epigenetic Mechanisms of Transcriptional Deregulation in Unfavorable NeuroblastomasKai-Oliver Henrich, Sebastian Bender, Maral Saadati, et al.
Leukemia|October 3, 2023
Correction: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patientsEkaterina Jahn, Maral Saadati, Pierre Fenaux, et al.
Leukemia|August 17, 2023
Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patientsEkaterina Jahn, Maral Saadati, Pierre Fenaux, et al.
Hemasphere|January 16, 2025
Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with <i>NPM1</i>-mutated AMLSibylle Cocciardi, Maral Saadati, Nina Weiß, et al.
Leukemia|August 3, 2022
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trialNikolaus Jahn, Ekaterina Jahn, Maral Saadati, et al.
Blood Advances|April 29, 2022
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplicationsHartmut Döhner, Daniela Weber, Julia Krzykalla, et al.
Blood|January 6, 2026
Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemiaHartmut Döhner, Daniela Späth, Maral Saadati, et al.
Pageof 4